Acinetobacter pneumonia: Is the outcome different from the pneumonias caused by other agents

Basit Öğe Kaydı
dc.authorwosid, Osman/AGR-7980-2022
dc.authorwosid, osman/HRD-6024-2023
dc.contributor.authorEdis, Ebru Cakir
dc.contributor.authorHatipoglu, Osman N.
dc.contributor.authorTansel, Ozlem
dc.contributor.authorSut, Necdet
dc.date.accessioned2024-06-12T10:50:28Z
dc.date.available2024-06-12T10:50:28Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground : The principal aim of the present study was to determine whether Acinetobacter spp. pneumonia differs from hospital-acquired pneumonias (HAPs) caused by other agents with respect to therapeutic success and survival rate. METHODS : This study includes 140 adult patients diagnosed with HAPs caused by identified etiologic agents between March 2005 and February 2006. These patients were divided into two groups according to the agent responsible for their infection (Acinetobacter spp. [n = 63] or non-Acinetobacter spp. [n = 77]). The groups were compared in terms of risk factors, therapeutic success and six-week survival rates. Results : Previous antibiotic use and the risk of aspiration were independent factors responsible for the development of Acinetobacter spp. pneumonia. Hypoalbuminemia, steroid use and the use of a mechanical ventilator were determined to be mortality-associated independent risk factors for Acinetobacter spp. pneumonia. The clinical success rate at the end of therapy was 41.6 and, at the sixth week, the survival rate was 35 among patients in whom Acinetobacter spp. was the causative agent. Conversely, in the control group, these values were 43 and 32, respectively ( P > 0.05). We found that the use of the appropriate antibiotics for the treatment of Acinetobacter spp. pneumonia was an important factor in survival ( P < 0.001). Conclusion : The outcomes of Acinetobacter spp. pneumonia do not differ from HAPs associated with non-Acinetobacter spp. in terms of therapeutic success and survival rates.en_US
dc.identifier.doi10.4103/1817-1737.62472
dc.identifier.endpage96en_US
dc.identifier.issn1817-1737
dc.identifier.issn1998-3557
dc.identifier.issue2en_US
dc.identifier.pmid20582174en_US
dc.identifier.scopus2-s2.0-77956023741en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage92en_US
dc.identifier.urihttps://doi.org/10.4103/1817-1737.62472
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17991
dc.identifier.volume5en_US
dc.identifier.wosWOS:000283441100007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofAnnals Of Thoracic Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcinetobacter Sppen_US
dc.subjectHospital-Acquired Pneumoniaen_US
dc.subjectRisk Factorsen_US
dc.subjectSurvivalen_US
dc.subjectTherapeutic Successen_US
dc.subjectVentilator-Associated Pneumoniaen_US
dc.subjectIntensive-Care-Uniten_US
dc.subjectRisk-Factorsen_US
dc.subjectBaumanniien_US
dc.subjectInfectionen_US
dc.subjectMortalityen_US
dc.titleAcinetobacter pneumonia: Is the outcome different from the pneumonias caused by other agentsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu